根据总部位于剑桥的跨国制药巨头阿斯利康（AstraZeneca）的说法，如果香港能够建立起新的医疗保健金融模式，那么该地区将能够吸引更多的全球生物技术投资。
Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant.
近年来，尽管全球制药公司都在加大对中国内地的投资力度，但阿斯利康在过去三年中仍将超过60项临床试验项目引入香港，并投入了超过2亿港元（约合2550万美元）。
While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over the past three years.
该公司肿瘤业务执行副总裁大卫·弗雷德里克森（David Fredrickson）在接受《南华早报》独家采访时表示：“香港拥有出色的科研实力和现代化的监管体系。现在，香港需要确保有相应的资金支持这些科研活动，这样才能继续吸引更多的研发投资。”弗雷德里克森认为，这些“现代化的资金”可以来自公共财政，其目的在于帮助癌症患者负担得起个性化的医疗服务和尖端治疗方法。
Hong Kong was still a key research and development hub for the firm, David Fredrickson, executive vice-president of oncology business, said in an exclusive interview with the South China Morning Post.
目前，这家全球市值第七大的制药公司正在推动将肺癌筛查纳入香港的政府资助筛查计划中。自2004年该计划启动以来，香港已经覆盖了宫颈癌、结直肠癌和乳腺癌的筛查项目。
“Hong Kong has great science and a modern regulatory system,” he said. “[It] now needs to make sure there’s modern funding to go along with that, then I think that is a very compelling opportunity to continue to attract research and development investment.”The “modern funding”, which could come from public dollars, is supposed to be able to help cancer patients access personalised medicine and cutting-edge treatments out of pocket, according to Fredrickson.
弗雷德里克森强调了早期发现对肺癌治疗的重要性：如果患者能在早期（如第1期）被诊断出来，五年生存率可高达80%；而那些在晚期（第4期）才被诊断出的患者，五年生存率则仅有约15%。早期筛查有助于患者节省医疗费用，从而享受更好的生活质量。
It comes as the world’s seventh-largest pharmaceutical company by market capitalisation is promoting the inclusion of lung cancer in the government-backed screening programmes in Hong Kong, a scheme that currently covers cervical cancer, colorectal and breast screenings since the launch in 2004.
根据香港中文大学临床肿瘤学系副教授Herbert Loong的研究结果，接受低剂量计算机断层扫描（CT）检查后，吸烟者每增加一质量调整生命年（QALY）所需的费用为14,122美元；而高风险的非吸烟者每增加一QALY所需的费用仅为9,610美元。这一费用远低于筛查前的预估成本（24,302至40,202美元）。
Fredrickson highlighted the effect of early-stage detection for lung cancer treatment. If a patient is diagnosed early, like at stage 1, the five-year survival rate could be as high as 80 per cent, versus around 15 per cent for those who are diagnosed late at stage 4.
根据医院管理局的数据，2023年肺癌成为香港最常见的癌症类型，全年新增病例6,111例，死亡人数为3,880人。
Early screening is estimated to help patients save spending to enjoy quality life.
这位阿斯利康公司的高管表示：“香港特首已将肺癌筛查列为优先事项，并呼吁制定具体的实施计划，同时设定严格的截止日期，以切实改善居民的健康状况。”
After low-dose computed tomography, a smoker needs US$14,122 per quality-adjusted life-year (QALY), while a high-risk non-smoker would spend US$9,610 per QALY, far lower than the pre-screening threshold of US$24,302 to US$40,202, according to Herbert Loong, associate professor in the department of clinical oncology of The Chinese University of Hong Kong.
在6月份的一次简报会上，由卫生局局长Lo Chung-mau主持的癌症协调委员会提到，已委托当地大学开展研究，以制定适合香港的肺癌筛查策略。
In 2023, lung cancer was the most common and fatal cancer in Hong Kong, with 6,111 new cases and 3,880 deaths recorded in the year, data from the Hospital Authority showed.
目前，全球约有11个地区（从英国到加拿大再到台湾）都实施了针对肺癌的筛查项目。Fredrickson指出：“全球范围内，人们越来越重视肺癌筛查工作，并愿意投入更多资源。”
“The Chief Executive of Hong Kong has made lung cancer screening a priority,” said the AstraZeneca executive, while calling for a concrete implementation plan with a strict deadline to deliver real outcomes for residents.
这位阿斯利康高管还强调，除了早期检测外，香港还需要个性化医疗以及用于研发新药物的资金支持。
In a June briefing, the Cancer Coordinating Committee chaired by Lo Chung-mau, the Secretary for Health, mentioned that a local university had been commissioned to conduct a study for developing local lung cancer screening strategies.
Fredrickson表示：“如果各方能够共同努力，我相信香港一定能够在抗击肺癌方面取得进展。”
Meanwhile, lung-focused screening schemes are available in about 11 regions globally, spanning from the UK to Canada to Taiwan. “There is growing global momentum to put resources behind lung cancer screening,” said Fredrickson.
肿瘤治疗业务是阿斯利康公司的核心业务之一，该业务上半年为公司带来了141亿美元的收入，占公司总收入的46%。截至7月27日，阿斯利康的研发管线中共有183个项目，其中111个项目与癌症治疗相关。（译文说明：
Besides early detection, Hong Kong also needed personalised medicine and funding for new drugs, the AstraZeneca executive noted.
- 采用简体中文表达；
“If they can come together, I am confident that Hong Kong will have an opportunity to make progress against lung cancer,” said Fredrickson.
- 保留了原文的所有段落结构；
The oncology business is a major driver for AstraZeneca, contributing 46 per cent of total revenue by earning US$14.1 billion in the first half of the year. The cancer-related candidates also accounted for 111 out of 183 projects in the pharmaceutical giant’s pipeline as of July 27.
- 确保翻译内容符合中文阅读习惯。）
By Themis Qi